Trade Names
Synonyms
Status
Molecule Category Free-form
ATC A10BB12
UNII 6KY687524K
EPA CompTox DTXSID5040675

Structure

InChI Key WIGIZIANZCJQQY-RUCARUNLSA-N
Smiles CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O
InChI
InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

Physicochemical Descriptors

Property Name Value
Molecular Formula C24H34N4O5S
Molecular Weight 490.63
AlogP 3.07
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 7.0
Polar Surface Area 124.68
Molecular species ACID
Aromatic Rings 1.0
Heavy Atoms 34.0

Bioactivity

Mechanism of Action Action Reference
Sulfonylurea receptor 1, Kir6.2 blocker BLOCKER PubMed PubMed PubMed DailyMed
Protein: Sulfonylurea receptor 1, Kir6.2

Description: ATP-binding cassette sub-family C member 8

Organism : Homo sapiens

Q09428 ENSG00000006071
Protein: Sulfonylurea receptor 1, Kir6.2

Description: ATP-sensitive inward rectifier potassium channel 11

Organism : Homo sapiens

Q14654 ENSG00000187486
Assay Description Organism Bioactivity Reference
DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide) None 100.0 nM DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide) None 11.0 nM
PubChem BioAssay. insulin secretion from INS-1E cells in the presence of 5 mM glucose-IC50. (Class of assay: confirmatory) None 4.06 nM
Hypoglycemic activity in diabetic rat model assessed as decrease in blood glucose level at 20 mg/kg, ig administered for 12 days measured on third day of compound dosing by glucometer relative to control Rattus norvegicus 7.86 %
Hypoglycemic activity in diabetic rat model assessed as decrease in blood glucose level at 20 mg/kg, ig administered for 12 days measured on sixth day of compound dosing by glucometer relative to control Rattus norvegicus 7.86 %
Hypoglycemic activity in diabetic rat model assessed as decrease in blood glucose level at 20 mg/kg, ig administered for 12 days measured on ninth day of compound dosing by glucometer relative to control Rattus norvegicus 7.86 %
Hypoglycemic activity in diabetic rat model assessed as decrease in blood glucose level at 20 mg/kg, ig administered for 12 days measured on twelfth day by glucometer relative to control Rattus norvegicus 7.86 %
Agonist activity at SUR in Wistar rat pancreatic islets assessed as increase in insulin secretion at 5 to 20 uM incubated for 1 hr followed by glucose addition for 30 mins by quantitative sandwich enzyme immunoassay Rattus norvegicus 790.0 nM
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600) Staphylococcus aureus subsp. aureus 15.98 %
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600) Escherichia coli 1.16 %
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600) Klebsiella pneumoniae 11.97 %
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600) Pseudomonas aeruginosa 13.41 %
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600 Acinetobacter baumannii 22.8 %
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630 Candida albicans 1.98 %
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570) Cryptococcus neoformans -2.89 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens -4.62 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 8.644 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.17 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.17 %
Inhibition of N-terminal His-tagged human AKR1C3 expressed in Escherichia coli BL21(Condon Plus) competent cells using 9,10-phenanthrenequinone as substrate in presence of NADPH Homo sapiens 850.0 nM

Cross References

Resources Reference
ChEBI 5383
ChEMBL CHEMBL1481
DrugBank DB00222
DrugCentral 1300
FDA SRS 6KY687524K
Guide to Pharmacology 6820
SureChEMBL SCHEMBL16086
ZINC ZINC000100070954